<DOC>
	<DOCNO>NCT00730522</DOCNO>
	<brief_summary>The objective study demonstrate large proportion vigabatrin-treated subject placebo-treated subject methamphetamine-free last 2 week study 's Treatment Phase ( Weeks 11 12 ) .</brief_summary>
	<brief_title>Safety Efficacy Study Vigabatrin Treat Methamphetamine Dependence</brief_title>
	<detailed_description>This Phase II , randomize , double-blind , placebo-controlled , intent-to-treat , 2-arm , parallel design , multicenter study evaluate vigabatrin treatment methamphetamine addiction . The study involve approximately 180 subject ( 90/group ) meet DSM IV criterion methamphetamine dependence . Subjects evaluate compliance protocol inclusion/exclusion criterion Screening/Baseline Phase , last 4 week . At conclusion Screening/Baseline Phase , subject meet inclusion/exclusion criterion randomize one two treatment group : vigabatrin placebo . Subjects proceed 12 week Treatment Phase undergo 12 week follow-up period . Subjects schedule clinic visit 3 time per week efficacy and/or safety assessment Screening/Baseline Phase 12 week Treatment Phase . Subjects return follow visit Weeks 13 , 16 , 20 24 .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>Able understand study provide write informed consent . Male female least 18 year age . Meets DSMIV ( Diagnostic Statistical Manual Mental Disorders Fourth Edition ) criteria methamphetamine dependence major diagnosis , determine Substance Abuse module SCID ( Structured Clinical Interview DSMIV ) . Provides least one urine specimen positive methamphetamine accord rapid screening test . Seeking treatment methamphetamine dependence . Have normal visual field . Be generally good health base history , physical examination laboratory finding . If female childbearing potential , use acceptable contraceptive method Has current dependence psychoactive substance methamphetamine , alcohol , nicotine , cannabinoid physiologic dependence alcohol require medical detoxification . Has serious medical psychiatric illness and/or clinically significant abnormal laboratory value . Has history serious cardiovascular reaction methamphetamine . Has clinically significant cardiovascular impairment , abnormal ECG uncontrolled hypertension . Be court governmental agency ( e.g . social service ) mandate obtain treatment require outside urine monitoring . Be enrol opiate substitution treatment program within 2 month randomization . Has ever take vigabatrin past . Is pregnant lactating . Has clinically significant ophthalmologic disease , would preclude safety monitoring , undergoing treatment ocular disease intend ocular surgery procedure perform time participation trial . Has receive drug know major organ toxicity , include retinotoxicity . Is currently participate , enrol another clinical trial within last 30 day . Be anyone , judgment investigator , would expect attend regular study visit complete study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>Dependency</keyword>
	<keyword>Addiction</keyword>
	<keyword>vigabatrin</keyword>
</DOC>